Viewing Study NCT06743503

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:11 PM
Ignite Modification Date: 2026-02-19 @ 5:31 PM
Study NCT ID: NCT06743503
Status: RECRUITING
Last Update Posted: 2025-09-18
First Post: 2024-12-10
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Sponsor: Nanjing IASO Biotechnology Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Large B-cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None UB-VV400 View
None relapsed or refractory View
None Large B-cell Lymphoma View